Table 1. Model parameters.

Parameter	Description	Value
m	Mosquitoes per human Nm/Nh (dimensionless)	2435/625 [50]
a	Biting rate (day−1)	0.21 [39]
b	Transmission probability from an infected mosquito to a susceptible human (dimensionless)	0.5 [51]
η	Treatment coverage (dimensionless)	0-1
σf	Proportion of symptomatic humans infected by P. falciparum (dimensionless)	0.9 [52]
σv	Proportion of symptomatic humans infected by P. vivax (dimensionless)	0.33 [53]
rf	Recovery rate of untreated infected-humans by P. falciparum (day−1)	1/287 [50]
rv	Recovery rate of untreated infected-humans by P. vivax (day−1)	1/60 [54]
γf	Progression rate from infected to post-treatment humans affected by P. falciparum (day−1)	1/2 [50]
γv	Progression rate from infected to post-treatment humans affected by P. vivax (day−1)	1/9 [36, 55]
φ	Proportion of treated humans with primaquine (dimensionless)	0-1
κ	Protective period of the treatment (day)	see Table 2
ϵf	Infectious period of post-treatment humans infected by P. falciparum (day)	see Table 2
ϵv	Infectious period of post-treatment humans infected by P. vivax (day)	see Table 2
α	Resistance cost (dimensionless)	0-0.6 [24]
n	Recurrences produced by the resistant strain (dimensionless)	1
Λm	Mosquito birth rate (day−1)	0.033 [50]
μm	Mosquito death rate (day−1). We assumed constant population	0.033
ca	Transmission probability from an asymptomatic human to susceptible mosquito (dimensionless)	0.12 [56]
cs	Transmission probability from an infected-symptomatic human to susceptible mosquito (dimensionless)	0.4 [56]
ν	Probability of transmitting a resistant parasite from a post-treatment infected by a sensitive strain (dimensionless)	see Table 2
ψ	Hypnozoite relapse rate (day−1). We assumed tropical relapses	1/60 [57]
ρsr	Probability of developing sensitive infection by the contact between an infected mosquito by sensitive strain and a human with latent parasites of the resistant strain (dimensionless)	0.5
ρrs	Probability of developing resistant infection by the contact between an infected mosquito by resistant strain and a human with latent parasites of the sensitive strain (dimensionless)	0.5
ϕt	Probability of post-treatment human of remaining with latent parasites (dimensionless)	0.21 [58]
ϕu	Probability of an untreated-infected human of remaining with latent parasites (dimensionless)	0.4-0.9 [59]
μvl	Clearance rate of latent parasites (hypnozoites) day−1	1/425 [39]